Chronic Obstructive Pulmonary DiseaseNCT00792974
End-of-Life Fear in Patients With End-Stage Lung Disease (COPD)
An observational study of Chronic Obstructive Pulmonary Disease and End-of-Life Fear, run by Philipps University Marburg at 2 sites in Germany.
Trial summary
The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life. Afterwards, the patients receive a brief psychological intervention to develop coping strategies for chronic illness. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Obstructive Pulmonary Disease, End-of-Life Fear, Fear About Death and Dying
- What is being tested?
- A brief psycho-educational intervention
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 199 participants
- Where
- 2 sitesGermany
- Study dates
- Oct 2008to Jul 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use auf administrative databases. All patients who are alert and can provide consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons in match-able age.
Who may be able to join
- 50 years or older
- COPD diagnosis III and IV by GOLD-criteria with or without an indication for long-term oxygen therapy (LTOT), non invasive ventilation (NIV) and/or lung transplantation (LTx)
- COPD diagnosis II by GOLD-criteria
- Patients with hip prosthesis
- Mental healthy people, who have no severe illness (such as heart disease or cancer) one year before
Who cannot join
- Participation in other studies likely to influence the patient in terms of confounding effects
- Acute and severe exacerbations with hard symptoms over 4 days
- Patients need a increasing medication of steroids and/or antibiotics
- Non-compliance
Trial locations and contacts
2 sites in 1 country.
Sabine R Pinzer, Dipl.-Psych. contact
Germany2 sites, 2 recruiting
- Recruiting
Department of Clinical Psychology and Psychotherapy, Philipps University Marburg
Marburg, 35032
Winfried Rief, Prof. Dr., rief@staff.uni-marburg.de
Sabine R Pinzer, Dipl.-Psych., pinzer@staff.uni-marburg.de
- Recruiting
Klinikum Berchtesgadener Land, Schön Kliniken
Schönau am Königssee, 83471
Klaus Kenn, Dr., kkenn@schoen-kliniken.de
Sabine R Pinzer, Dipl.-Psych., spinzer@schoen-kliniken.de
About this study
Official title: End-of-Life Fear in Patients With End-Stage Lung Disease: Fears of Death and Dying, Wishes and Needs of Patients With Severe COPD
The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life. Afterwards, the patients receive a brief psychological intervention to develop coping strategies for chronic illness. Beside this a general purpose of this intervention is to improve patients' quality of life.
Read the detailed description
Background:
COPD-related mortality differs markedly from that of other chronic diseases. While the mortality rates for heart disease and stroke have fallen significantly, death rates caused by COPD have more than doubled. Therefore there is a major need to address questions of palliative end-of-life care. Patients with end-stage pulmonary lung diseases suffer from dyspnea, severe pain, fatigue and - the "deadlock" in end-of-life communication. Many people with severe COPD are socially isolated, have low quality of life and psychosocial challenges such as sadness, panic or hopelessness. In fact, 70 up to 90% suffer from a clinically relevant depression and/or anxiety disorder. Despite this, the majority of COPD patients with co-morbid disorders don't receive any treatment for their psychological symptoms. Furthermore, there is substantial evidence that only a minority of people with end-stage COPD have the opportunity to discuss their fears and wishes for end-of-life care. The few existing studies on this issue demonstrated that the majority of people with severe COPD wants to discuss topics such as prognosis, fear of death and dying or preferences and needs at the end-of-life. Understanding the nature and implications of treatment options is an important component of advanced care planning for people with end-stage lung disease.
Therefore the aim of this study is to bring up the end-of-life communication to patients with end-stage COPD. We hypothesize that end-stage COPD patients have greater fear of death and dying as patients with mild to moderate COPD or with hip prothesis (control group). The lowest anxiety rate with regard to death should be found in the healthy control group. Furthermore, a brief psychological intervention should decrease the co-morbid psychological symptoms and patients' fears. Higher quality of life should be achieved.
Objectives:
Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use of administrative databases. All patients providing informed consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons matched for age and sex. As we want to start a first feasibility intervention study, this is a clinical controlled design without randomization.
Methods:
Initially a systematic literature review was performed to determine what methods are being used in COPD studies and how the patients' views can be best assessed. Then a qualitative multi-method design will be used involving semi-structured interviews, standardized questionnaires and lung function parameters.
The face-to-face interview includes ten categories with more than 70 questions on
- social demography
- actual health status
- knowledge and wishes of further information about the disease
- thoughts and attitudes about the illness
- fears about the illness, treatment and prognosis
- general experiences of death and dying
- own experiences with death and dying
- fear of death
- fear of dying
- end-of-life decisions such as wishes and needs
Patients will be interviewed by a single interviewer. Each question will be read by using everyday language. Interviews will be audiotaped to control for integrity. Each interview will last approximately 60 minutes. The interview will be validated by the COPD-Anxiety-Questionnaire (CAF). To assess the patients cognitions about death, a self-report questionnaire, FIMEST, will be also used.
Standardized questionnaires will be used to detect depression or panic disorders by the Hospital Anxiety and Depression Scale. Functional health status will be measured by the Patients Health Questionnaire (PHQ) and the COPD-Disability- Index (CDI). The condition specific questionnaire, the Short Form-36 Health Survey (SF-36) and Euroqol (EQ) will be compared for their discriminative and evaluative properties. Spirometric tests and a walking test will be also performed.
After the interview those patients who have increased death anxiety take part in a brief psychological intervention to discuss their end-of-life issues, worries and fears. For this psychological intervention, a manualized 2-3-session approach will be used.
- Conditions
- Chronic Obstructive Pulmonary Disease, End-of-Life Fear, Fear About Death and Dying, Depression
- Being tested
- A brief psycho-educational intervention
- Keywords
- Cognitive behavioral education, COPD (Chronic Obstructive Pulmonary Disease), GOLD II-IV
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
A brief psycho-educational interventionBehavioural
Also called Cognitive-behavioral therapy, Palliative care
A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.
This study is an open pilot study ("feasibility study") to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment.
| Study group | Role | What they receive |
|---|---|---|
| COPD by GOLD-criteria III and IV | Not described Receives: Behavioral: A brief psycho-educational intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Self-reported semi-structured interview about the fear of death and dying, needs and wishes at the end-of-life in patients with severe COPD
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Secondary outcomes (17)
St. George's Respiratory Questionnaire (SGRQ)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Short Form Health Survey (Fragebogen zum allgemeinen Gesundheitszustand, SF-36)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Euroqol (EQ)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Patient Health Questionnaire (PHQ)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Hospital Anxiety and Depression Scale (HADS)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Borg Scale
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Diffusion capacity (DLCO)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Blood gas analysis (BGA)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Bodyplethysmographs
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Bio-Impedance-Analysis (BIA)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
6-Minute Walk Distance (6 MWD)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Body Mass Index (BMI)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Blood tests
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Multidimensional assessment of attitudes toward death and dying (Fragebogeninventar zur mehrdimensionalen Erfassung des Erlebens gegenüber Sterben und Tod, FIMEST)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
COPD- Anxiety -Questionnaire (COPD-Angst-Fragebogen, CAF)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
COPD- Disability- Index (CDI)
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Differences in COPD admission rates, functional impairment, quality of life and end-of-life fear after treatment
Measured: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2008 (estimated)
- Study startOct 2008
- Primary completionJul 2010 (estimated)
- Study completionJul 2010 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Obstructive Pulmonary DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 199 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Philipps University Marburg
- Sponsor type
- University, hospital or other
- Collaborators
- AstraZeneca
- Investigators
- Winfried Rief, Prof. Dr., Principal investigator, Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, GermanyKlaus Kenn, Dr., Study director, Klinikum Berchtesgadener Land, Schön Kliniken, Schönau a. K., GermanySabine R Pinzer, Dipl.-Psych., Study chair, Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Germany
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00792974
- Sponsor's protocol ID
- EoL
- Status last verified
- Feb 2009
- First submitted
- 17 Nov 2008
- Last updated
- 5 Feb 2009
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Feb 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- End-of-Life Fear in Patients With End-Stage Lung Disease: Fears of Death and Dying, Wishes and Needs of Patients With Severe COPD
- ClinicalTrials.gov ID
- NCT00792974
- Acronym / sponsor ID
- EoL
- Conditions
- Chronic Obstructive Pulmonary Disease, End-of-Life Fear, Fear About Death and Dying, Depression
- Keywords
- Cognitive behavioral education, COPD (Chronic Obstructive Pulmonary Disease), GOLD II-IV
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 199 participants (estimated)
- Lead sponsor
- Philipps University MarburgUniversity, hospital or other
- Collaborators
- AstraZeneca
- Study start
- Oct 2008
- Primary completion
- Jul 2010 (estimated)
- Study completion
- Jul 2010 (estimated)
- First posted
- 18 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to develop an interview to ask patients with COPD about their fear of death and dying, their needs and wishes at the end-of-life. Afterwards, the patients receive a brief psychological intervention to develop coping strategies for chronic illness. Beside this a general purpose of this intervention is to improve patients' quality of life.
Detailed description
Background:
COPD-related mortality differs markedly from that of other chronic diseases. While the mortality rates for heart disease and stroke have fallen significantly, death rates caused by COPD have more than doubled. Therefore there is a major need to address questions of palliative end-of-life care. Patients with end-stage pulmonary lung diseases suffer from dyspnea, severe pain, fatigue and - the "deadlock" in end-of-life communication. Many people with severe COPD are socially isolated, have low quality of life and psychosocial challenges such as sadness, panic or hopelessness. In fact, 70 up to 90% suffer from a clinically relevant depression and/or anxiety disorder. Despite this, the majority of COPD patients with co-morbid disorders don't receive any treatment for their psychological symptoms. Furthermore, there is substantial evidence that only a minority of people with end-stage COPD have the opportunity to discuss their fears and wishes for end-of-life care. The few existing studies on this issue demonstrated that the majority of people with severe COPD wants to discuss topics such as prognosis, fear of death and dying or preferences and needs at the end-of-life. Understanding the nature and implications of treatment options is an important component of advanced care planning for people with end-stage lung disease.
Therefore the aim of this study is to bring up the end-of-life communication to patients with end-stage COPD. We hypothesize that end-stage COPD patients have greater fear of death and dying as patients with mild to moderate COPD or with hip prothesis (control group). The lowest anxiety rate with regard to death should be found in the healthy control group. Furthermore, a brief psychological intervention should decrease the co-morbid psychological symptoms and patients' fears. Higher quality of life should be achieved.
Objectives:
Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use of administrative databases. All patients providing informed consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons matched for age and sex. As we want to start a first feasibility intervention study, this is a clinical controlled design without randomization.
Methods:
Initially a systematic literature review was performed to determine what methods are being used in COPD studies and how the patients' views can be best assessed. Then a qualitative multi-method design will be used involving semi-structured interviews, standardized questionnaires and lung function parameters.
The face-to-face interview includes ten categories with more than 70 questions on
- social demography
- actual health status
- knowledge and wishes of further information about the disease
- thoughts and attitudes about the illness
- fears about the illness, treatment and prognosis
- general experiences of death and dying
- own experiences with death and dying
- fear of death
- fear of dying
- end-of-life decisions such as wishes and needs
Patients will be interviewed by a single interviewer. Each question will be read by using everyday language. Interviews will be audiotaped to control for integrity. Each interview will last approximately 60 minutes. The interview will be validated by the COPD-Anxiety-Questionnaire (CAF). To assess the patients cognitions about death, a self-report questionnaire, FIMEST, will be also used.
Standardized questionnaires will be used to detect depression or panic disorders by the Hospital Anxiety and Depression Scale. Functional health status will be measured by the Patients Health Questionnaire (PHQ) and the COPD-Disability- Index (CDI). The condition specific questionnaire, the Short Form-36 Health Survey (SF-36) and Euroqol (EQ) will be compared for their discriminative and evaluative properties. Spirometric tests and a walking test will be also performed.
After the interview those patients who have increased death anxiety take part in a brief psychological intervention to discuss their end-of-life issues, worries and fears. For this psychological intervention, a manualized 2-3-session approach will be used.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| COPD by GOLD-criteria III and IV | – | Behavioral: A brief psycho-educational intervention |
Who may qualify
- Ages
- 50 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects are recruited from the Pulmonary Rehabilitation Units of the Berchtesgadener Klinikum Schönau, Germany, through direct recruitment and use auf administrative databases. All patients who are alert and can provide consent are invited to participate, if they have a chronic obstructive pulmonary disease with stage II, III or IV by GOLD-criteria. An open three group comparison is made of one-hundred patients with severe COPD (stage III and IV), thirty-three patients with moderate COPD (stage II), thirty-three patients with hip prosthesis and thirty-three mental healthy persons in match-able age.
Key inclusion criteria (5 listed)
- 50 years or older
- COPD diagnosis III and IV by GOLD-criteria with or without an indication for long-term oxygen therapy (LTOT), non invasive ventilation (NIV) and/or lung transplantation (LTx)
- COPD diagnosis II by GOLD-criteria
- Patients with hip prosthesis
- Mental healthy people, who have no severe illness (such as heart disease or cancer) one year before
Key exclusion criteria (4 listed)
- Participation in other studies likely to influence the patient in terms of confounding effects
- Acute and severe exacerbations with hard symptoms over 4 days
- Patients need a increasing medication of steroids and/or antibiotics
- Non-compliance
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| A brief psycho-educational interventionAlso: Cognitive-behavioral therapy, Palliative careA brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques. This study is an open pilot study ("feasibility study") to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment. | Behavioural | COPD by GOLD-criteria III and IV |
Primary outcome
Self-reported semi-structured interview about the fear of death and dying, needs and wishes at the end-of-life in patients with severe COPD
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
17 secondary outcomes
St. George's Respiratory Questionnaire (SGRQ)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Short Form Health Survey (Fragebogen zum allgemeinen Gesundheitszustand, SF-36)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Euroqol (EQ)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Patient Health Questionnaire (PHQ)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Hospital Anxiety and Depression Scale (HADS)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Borg Scale
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Diffusion capacity (DLCO)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Blood gas analysis (BGA)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Bodyplethysmographs
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Bio-Impedance-Analysis (BIA)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
6-Minute Walk Distance (6 MWD)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Body Mass Index (BMI)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Blood tests
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Multidimensional assessment of attitudes toward death and dying (Fragebogeninventar zur mehrdimensionalen Erfassung des Erlebens gegenüber Sterben und Tod, FIMEST)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
COPD- Anxiety -Questionnaire (COPD-Angst-Fragebogen, CAF)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
COPD- Disability- Index (CDI)
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Differences in COPD admission rates, functional impairment, quality of life and end-of-life fear after treatment
Time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Feb 2009.
Related trials for Chronic Obstructive Pulmonary Disease
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sabine R Pinzer, Dipl.-Psych. contact
Winfried Rief, Prof. Dr. principal investigator
Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Germany
Klaus Kenn, Dr. study director
Klinikum Berchtesgadener Land, Schön Kliniken, Schönau a. K., Germany
Sabine R Pinzer, Dipl.-Psych. study chair
Department of Clinical Psychology and Psychotherapy, Philipps University Marburg, Germany
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Obstructive Pulmonary Disease and End-of-Life Fear, run by Philipps University Marburg at 2 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 5 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Winfried Rief, Prof. Dr. (+49-6421-2823657, rief@staff.uni-marburg.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Self-reported semi-structured interview about the fear of death and dying, needs and wishes at the end-of-life in patients with severe COPD (time frame: Pre-Post-Design including 2 assessment points: pre-treatment and post-treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Feb 2009.